Kimberly Desantis, MD
Family Medicine · Endwell, NYNPI 1376578724
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 44.6% of the total.
Across 321 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$679
- Pfizer$452
- GSK$223
- Lilly USA, LLC$170
- Abbott$153
- plus $1K from 25 others
Across 335 payments — averaging $3358.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$967K
- Modernatx, Inc.$107K
- AstraZeneca$28K
- Astrazeneca UK Limited$23K
What the payments were for
- Food & beverage$4,939100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 115 | $2,204 |
| Novo Nordisk | 45 | $679 |
| Pfizer | 62 | $452 |
| GSK | 20 | $223 |
| Lilly USA, LLC | 8 | $170 |
| Abbott | 10 | $153 |
| Amgen | 9 | $152 |
| Stryker | 1 | $139 |
| Phathom Pharmaceuticals, Inc. | 6 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $72 |
| Novartis | 4 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Corium, LLC | 4 | $46 |
| AstraZeneca | 3 | $45 |
| Merck | 2 | $42 |
| Irhythm Technologies, Inc. | 1 | $38 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $31 |
| Corcept Therapeutics | 2 | $30 |
| Exact Sciences | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Boehringer Ingelheim | 2 | $27 |
| Verona Pharma, Inc. | 1 | $24 |
| Nevro Corp. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Gilead | 1 | $14 |
| Si-bone, Inc. | 2 | $14 |
| Bayer | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $11 |
| Neuronetics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$139
How this compares
$4,939 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $210,653 |
| MounjaroTirzepatide | 52 | $105,327 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $67,750 |
| EliquisApixaban | 54 | $64,934 |
| TrulicityDulaglutide | 23 | $43,852 |
| JardianceEmpagliflozin | 29 | $33,870 |
| XareltoRivaroxaban | 25 | $26,467 |
| OxycontinOxycodone Hcl | 15 | $22,991 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $20,283 |
| EntrestoSacubitril/Valsartan | 13 | $15,894 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $15,121 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $11,055 |
| Levothyroxine Sodium | 478 | $8,961 |
| Atorvastatin Calcium | 647 | $8,501 |
| MyrbetriqMirabegron | 12 | $8,382 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $679 | $210,653109 claims |
| Lilly USA, LLCMounjaro, Trulicity | $170 | $149,17875 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $223 | $93,926136 claims |
| PfizerEliquis, Paxlovid | $452 | $68,88469 claims |
| Boehringer IngelheimJardiance | $27 | $33,87029 claims |
| NovartisEntresto | $53 | $15,89413 claims |
| AstraZenecaSymbicort | $45 | $7,69912 claims |
| AbbVieSynthroid | $2,204 | $5,29384 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in Endwell
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.